Disease Information

General Information of the Disease (ID: DIS00194)

• Name: Primary central nervous system lymphoma
• ICD: ICD-11: 2A8Z

Type(s) of Resistant Mechanism of This Disease

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Temozolomide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: hsa-mir-370 [1]

• Sensitive Disease: Primary central nervous system lymphoma [ICD-11: 2A8Z.0]
• Molecule Alteration: Expression; Up-regulation
• Sensitive Drug: Temozolomide
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Raji Burkitt cells; Bone; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Our study described a new miR-370-mediated mechanism of MGMT regulation in PCNSL. We first showed that miR-370 was downregulated in PCNSL tissues, while MGMT was inversely overexpressed. It was also observed that miR-370 suppressed the expression of MGMT. Additionally, upregulation of miR-370 significantly increased TMZ sensitivity dependent of MGMT, thus suppressed Raji cell proliferation and induced apoptosis in vitro. These results suggest that miR-370 is a potential target in PCNSL treatment.

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Methylated-DNA--protein-cysteine methyltransferase (MGMT) [1]

• Sensitive Disease: Primary central nervous system lymphoma [ICD-11: 2A8Z.0]
• Molecule Alteration: Expression; Down-regulation
• Sensitive Drug: Temozolomide
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Raji cells; Brain; Homo sapiens (Human); CVCL_0511
• In Vitro Model: Primary central nervous system lymphoma; Spinal cord; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Western blotting assay
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: miR-370 was downregulated in PCNSL tissues, while MGMT was inversely overexpressed.TMZ sensitivity consistently correlated with the overexpression of miR-370 and inhibition of MGMT; miR-370 affected PCNSL cell proliferation and increased apoptosis via MGMT.

Key Molecule: Methylated-DNA--protein-cysteine methyltransferase (MGMT) [1]

• Sensitive Disease: Primary central nervous system lymphoma [ICD-11: 2A8Z.0]
• Molecule Alteration: Expression; Down-regulation
• Sensitive Drug: Temozolomide
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Raji Burkitt cells; Bone; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Our study described a new miR-370-mediated mechanism of MGMT regulation in PCNSL. We first showed that miR-370 was downregulated in PCNSL tissues, while MGMT was inversely overexpressed. It was also observed that miR-370 suppressed the expression of MGMT. Additionally, upregulation of miR-370 significantly increased TMZ sensitivity dependent of MGMT, thus suppressed Raji cell proliferation and induced apoptosis in vitro. These results suggest that miR-370 is a potential target in PCNSL treatment.

References

• Ref 1: miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma .Pathol Oncol Res. 2020 Apr;26(2):707-714. doi: 10.1007/s12253-019-00605-4. Epub 2019 Feb 2. 10.1007/s12253-019-00605-4